A new study in Plastic and Reconstructive Surgery ↗, the field's leading journal, reports that abdominal body contouring outcomes are significantly worse for patients who reached their pre-surgery weight via combined bariatric surgery and GLP-1 receptor agonist treatment, the dominant weight-loss pathway of the obesity drug era. Five hundred fifty-two patients across more than a decade of records at a single academic institution show the pattern clearly: more weight loss, faster weight loss, and combined-modality weight loss all predict higher rates of seromas, hematomas, and unplanned returns to the operating room.
The data set. Retrospective cohort, 2013 through 2025, abdominal body contouring patients at a large academic center, stratified by their preoperative weight-loss method. Bariatric surgery alone, GLP-1 alone, or combined bariatric plus GLP-1. The combined-modality group had a total body weight loss of 28.6%, the highest of any cohort. They also lost it faster, at 0.95% TBWL per month. The straight-bariatric group came in at 24.1% TBWL. GLP-1 alone trailed both.
The complications. Higher absolute weight loss was an independent predictor of seroma (odds ratio 1.05 per percentage point, 95% CI 1.02 to 1.08, p=0.004) and overall composite complications (OR 1.03, p=0.017). Higher rate of weight loss was an independent predictor of seroma (OR 2.64, p=0.010). Combined bariatric plus GLP-1 use specifically, controlling for the absolute weight loss, was an independent predictor of seroma (OR 3.05, p=0.032), hematoma (OR 3.74, p=0.047), and unplanned return to the operating room (OR 6.78, p<0.001). The 6.78 number is the one to hold. A nearly seven-fold increase in unplanned reoperations is not a marginal signal.
The translation. Body contouring after massive weight loss has always carried higher complication rates than cosmetic abdominoplasty in stable-weight patients. The plastic surgery community knew that. What is new in the GLP-1 era is the speed of weight loss, the size of the patient population electing body contouring after rapid loss, and the fact that combined-modality patients lose weight differently than bariatric-only patients. The skin and subcutaneous tissue that had stretched to accommodate excess weight does not snap back uniformly. Faster loss leaves looser tissue. Looser tissue, when reshaped surgically, has more dead space. More dead space drains more fluid and bleeds more, and both make seromas, hematomas, and reoperations more likely.
The operational consequence. Plastic surgery practices that have built post-massive-weight-loss body contouring as a major revenue line over the past three years are about to confront higher complication rates than they expected, on patients who arrived faster and with less subcutaneous-tissue recovery time than the bariatric-only patients of the previous cycle. Some of this is fixable with longer pre-surgical waiting periods (giving tissue time to recover) and modified surgical technique (different drain protocols, different tension management). Some of it is structural and will reset the consent conversation. A 30% total body weight loss in 18 months on combined therapy is not equivalent, surgically, to the same 30% loss over four years on bariatric surgery alone.
What this should change. The American Society of Plastic Surgeons has not yet issued a formal post-GLP-1 body-contouring guidance. This paper is the kind of single-institution evidence that drives such guidance. Patients evaluating body contouring after GLP-1 therapy should know the complication rates are higher than the pre-2022 literature suggested, and surgeons should adjust both the timing and the technique of the operation to compensate. The drug class is not the problem. The pace it sets is.